A community pharmacy-based cardiovascular risk screening service implemented in Iran
- PMID: 28690693
- PMCID: PMC5499348
- DOI: 10.18549/PharmPract.2017.02.919
A community pharmacy-based cardiovascular risk screening service implemented in Iran
Abstract
Background: Cardiovascular disease is a major health concern around the world.
Objective: To assess the outcomes and feasibility of a pharmacy-based cardiovascular screening in an urban referral community pharmacy in Iran.
Methods: A cross sectional study was conducted in a referral community pharmacy. Subjects aged between 30-75 years without previous diagnose of cardiovascular disease or diabetes were screened. Measurement of all major cardiovascular risk factors, exercise habits, medical conditions, medications, and family history were investigated. Framingham risk score was calculated and high risk individuals were given a clinical summary sheet signed by a clinical pharmacist and were encouraged to follow up with their physician. Subjects were contacted one month after the recruitment period and their adherence to the follow up recommendation was recorded.
Results: Data from 287 participants were analyzed and 146 were referred due to at least one abnormal laboratory test. The results showed 26 patients with cardiovascular disease risk greater than 20%, 32 high systolic blood pressure, 22 high diastolic blood pressures, 50 high total cholesterol levels, 108 low HDL-C levels, and 22 abnormal blood glucose levels. Approximately half of the individuals who received a follow up recommendation had made an appointment with their physician. Overall, 15.9% of the individuals received medications and 15.9% received appropriate advice for risk factor modification. Moreover, 7.5% were under evaluation by a physician.
Conclusion: A screening program in a community pharmacy has the potential to identify patients with elevated cardiovascular risk factor. A plan for increased patient adherence to follow up recommendations is required.
Keywords: Cardiovascular; Cardiovascular Diseases; Community Pharmacy Services; Diagnostic Techniques; Iran; Mass Screening; Pharmacies.
Conflict of interest statement
CONFLICT OF INTEREST The manuscript is reviewed and approved by all the authors and no conflicts of interests have been declared.
Similar articles
-
Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.BMJ Open. 2019 Nov 10;9(11):e031246. doi: 10.1136/bmjopen-2019-031246. BMJ Open. 2019. PMID: 31712336 Free PMC article.
-
Cardiovascular risk screening program in Australian community pharmacies.Pharm World Sci. 2010 Jun;32(3):373-80. doi: 10.1007/s11096-010-9379-8. Epub 2010 Mar 10. Pharm World Sci. 2010. PMID: 20217476
-
Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals.J Am Pharm Assoc (2003). 2006 May-Jun;46(3):370-7. doi: 10.1331/154434506777069598. J Am Pharm Assoc (2003). 2006. PMID: 16739759
-
Participant and GP perspectives and experiences of screening for undiagnosed type 2 diabetes in community pharmacy during the Pharmacy Diabetes Screening Trial.BMC Health Serv Res. 2023 Dec 1;23(1):1337. doi: 10.1186/s12913-023-10269-1. BMC Health Serv Res. 2023. PMID: 38041094 Free PMC article.
-
Community pharmacy interventions for health promotion: effects on professional practice and health outcomes.Cochrane Database Syst Rev. 2019 Dec 6;12(12):CD011207. doi: 10.1002/14651858.CD011207.pub2. Cochrane Database Syst Rev. 2019. PMID: 31808563 Free PMC article.
Cited by
-
Development and Evaluation of an Educational Program for Community Pharmacists on Cardiovascular Risk Assessment.Risk Manag Healthc Policy. 2020 Jun 22;13:623-632. doi: 10.2147/RMHP.S231075. eCollection 2020. Risk Manag Healthc Policy. 2020. PMID: 32607030 Free PMC article.
-
Knowledge of cardiovascular disease risk factors and practice of primary prevention of cardiovascular disease by Community Pharmacists in Nigeria: a cross-sectional study.Int J Clin Pharm. 2018 Dec;40(6):1587-1595. doi: 10.1007/s11096-018-0744-3. Epub 2018 Nov 26. Int J Clin Pharm. 2018. PMID: 30474770 Free PMC article.
-
A systematic review of the role of community pharmacists in the prevention and control of cardiovascular diseases: the perceptions of patients.Syst Rev. 2023 Sep 14;12(1):160. doi: 10.1186/s13643-023-02338-7. Syst Rev. 2023. PMID: 37705090 Free PMC article.
-
Clinical and economic impacts of clinical pharmacists' interventions in Iran: a systematic review.Daru. 2019 Jun;27(1):361-378. doi: 10.1007/s40199-019-00245-8. Epub 2019 Jan 23. Daru. 2019. PMID: 30674033 Free PMC article.
-
Feasibility of cardiovascular risk screening in Portuguese community pharmacies.Pharm Pract (Granada). 2021 Apr-Jun;19(2):2255. doi: 10.18549/PharmPract.2021.2.2255. Epub 2021 May 25. Pharm Pract (Granada). 2021. PMID: 34188730 Free PMC article.
References
-
- Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, Ghanbili J, Ghanbarian A, Mehrabi Y, Saadat N, Salehi P, Mortazavi N, Heydarian P, Sarbazi N, Allahverdian S, Saadati N, Ainy E, Moeini S. Cardiovascular risk factors in an Iranian urban population: Tehran lipid and glucose study (phase 1) Soz Praventivmed. 2002;47(6):408–426. - PubMed
-
- Sarraf-Zadegan N, Boshtam M, Malekafzali H, Bashardoost N, Sayed-Tabatabaei FA, Rafiei M, Khalili A, Mostafavi S, Khami M, Hassanvand R. Secular trends in cardiovascular mortality in Iran, with special reference to Isfahan. Acta Cardiol. 1999;54(6):327–333. - PubMed
-
- O’Donovan DO, Byrne S, Sahm LJ. Pharmacist’s Use of Screening Tools to Estimate Risk of CVD: A Review of the Literature. Pharmacy. 2014;2(1):27–39. doi: 10.3390/pharmacy2010027. - DOI
LinkOut - more resources
Full Text Sources
Other Literature Sources